Lincare (LNCR) was downgraded from Hold to Sell, Deutsche Bank said. $24 price target. Company facing increased competition, and Medicare reimbursement rates may be reset lower.

Lincare (LNCR) was downgraded from Buy to Neutral, Oppenheimer said. Stock has risen lately, but the risk for lower Medicare oxygen payments remains.

Lincare Holdings Inc. announced its intention to commence an offering of up to $500 million convertible senior debentures.

Lincare intends to use up to approximately $150 million of the net proceeds from the issuance of the Debentures to acquire shares of its common stock concurrently with the offering and it may use additional proceeds for further stock repurchases following the offering.

Lincare Holdings (LNCR) was upgraded to Buy rating from Hold at Jefferies. Price target lifts to $40 from $37 and FY2008 eps estimates upped to $2.94 from $2.90.

Lincare (LNCR) was downgraded from Buy to Hold, Citigroup said. $37 price target. Medicare cap likely to be cut for oxygen.

Downgraded by Stifel Nicolaus from Buy to Hold

Upgraded by Matrix Research from Sell to Hold

Up 11 out of the past 12 years during the last week for an average of 2.39% per year. 1996 was the one down year.

0

biggest in their sector, consumer necessity